期刊文献+

清通补肾方脐疗对血液透析患者Klotho/FGF23轴的影响

下载PDF
导出
摘要 目的:观察清通补肾方脐疗对血液透析患者慢性肾脏病矿物质与骨异常的疗效及Klotho蛋白/成纤维细胞生长因子23轴的作用。方法:80例维持性血液透析的慢性肾脏病矿物质与骨异常患者随机分为对照组和清通补肾方脐疗组,对照组采用西医常规治疗方法加血液透析治疗加骨化三醇口服,清通补肾方脐疗组采用西医常规治疗方法加血液透析治疗加骨化三醇口服加清通补肾方脐疗,疗程共12周,观察治疗前后两组血钙、血磷、血甲状旁腺素(PTH)及Klotho蛋白、成纤维细胞生长因子23(FGF23)的水平。结果:清通补肾方脐疗组12周后血钙水平明显升高(P<0.01),血磷、PTH的水平低于于对照组(P<0.01或P<0.05),且血清Klotho蛋白表达水平明显高于对照组(P<0.01),同时血清FGF23水平明显低于对照组(P<0.01)。结论:清通补肾方能够明显改善并发CKD-MBD的血透患者的血钙、血磷、PTH等常规生化指标的水平,其作用机制可能与影响Klotho/FGF23轴的功能有关。
出处 《中国中西医结合肾病杂志》 2024年第8期701-703,共3页 Chinese Journal of Integrated Traditional and Western Nephrology
基金 盐城市医学科技发展计划项目(No.YK2020026)。
  • 相关文献

参考文献9

二级参考文献66

  • 1朱建民.继发性甲状旁腺功能亢进与高转化性肾性骨病[J].肾脏病与透析肾移植杂志,1996,5(1):50-55. 被引量:6
  • 2黄云辉,王丽.不同钠及超滤模式对血液透析患者低血压发生的影响[J].中国血液净化,2006,5(5):286-287. 被引量:6
  • 3刘宪莉,刘学东,张洪玲,宋立群.肾性骨病中西医治疗研究进展[J].医学研究杂志,2007,36(1):97-98. 被引量:3
  • 4Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int, 2006, 69: 1945-1953.
  • 5Kidney Disease: Improving Global Outcomes (KDIGO) CKD- MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD- MBD). Kidney Int Suppl, 2009, 113: S1-S130.
  • 6National Kidney Foundation. K/DOQ1 clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis, 2003, 42 (4 Suppl 3): S1 -S201.
  • 7Fan S, Ross C, Mitra S, et al. A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis[J]. Nephrol Dial Transplant, 2009, 24 (12): 3794-3799.
  • 8Ketteler M, Rix M, Fan S, et al. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis [J]. Clin J Am Soc Nephrol, 2008, 3 (4) : 1125-1130.
  • 9Hutchison A J, Maes B, Vanwalleghem J, et al. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6 month, randomized, comparative trial versus calcium carbonate [J]. Nephron Clin Pract, 2005, 100(1) : 8-19.
  • 10Hutchison AJ, Barnett ME, Krause R, et al. Long-term efficacy and safety profile of lanthanum carbonate: Results for up to 6 years of treatment [J]. Nephron Clin Pract, 2008, 110(1) : 15-23.

共引文献89

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部